Congratulations to the 2025 @IASLC, distinguished service award winners! Grateful for all the impact and happiness is the recognition at #WCLC25 for Drs. Sanja Dacic, Pasi Janne, @peters_solange and Wytold Rzyman!

Join us for the Year in Review Live Webinar | Targeted Therapy for Non-Small Cell Lung Cancer Edition on May 8, 4:30-6pm ET. Dr. Justin Gainor and I will discuss the latest updates with Dr. Neil Love to improve patient care and outcomes. #LCSM https://t.co/1FqK4JD3dB

#AACR24 @BhowmickNeil and Manish Thiruvalluvan present exciting work on persister cells in EGFR NSCLC @CSCancerCenter

👏 Attn: We have a new @AACRPres - clinician scientist extraordinaire, Dr. PatLoRusso! Dr. LoRusso outlined some of her priorities today; 🎯 ⬆️ outreach to patients 🎯 ⬆️ recruitment/retention of underrepresented researchers 🎯 @AACR Center for Cancer Clinical Trials #AACR24

Thank you @ConquerCancerFd #ASCO2023 @CSCancerCenter @CedarsSinaiMed

Improved PFS with talazoparib and atezolizumab maintenance for SFLN11 selected SCLC patients on S1929 #ASCO23 #LCSM

Enjoy hearing about progress in lung cancer research and treatment at #TTLC23. It does take a village. @DrRoyHerbstYale #LCSM

The @LungMAP trial has new leadership! @HosseinBorghaei of @FoxChaseCancer & @eaonc is new chair of the Lung-MAP master protocol. @ReckampK of @CedarsSinai & @SWOG is vice chair. @DrRoyHerbstYale & @JPatelMD are outgoing chair & vice chair @NCICTEP_ClinRes @CancerResrch @FNIH_Org

Congratulations to the @LungMAP team for 10 years of dedication and success. Teamwork and commitment to patients is the key. Excellent talk by @DrRoyHerbstYale at SWOG. It takes a village. @drgandara @JPatelMD Mary Redman, Vali Papadimitrakopoulou and so many others. #SWOG #LCSM

Dr. Karen Reckamp @ReckampK, Dr. Amin Mirhadi @aminmirhadi & Dr. Imai Taryne will chair the @_CurioScience_ interactive workshop “Opinions in Non-Targetable Early Stage #NSCLC” on 6/14 at 6-8pm PT. Please register via: workshops@curio-science.com. @CedarsSinai #CedarsSinaiCancer

It’s been refreshing to see colleagues and discuss the data at #ASCO2022 We are excited to see coverage #ASCODailyNews of the OS benefit for previously treated NSCLC with ramucirumab and pembrolizumab in S1800A @ASCO

#ASCO22 Pleased to present the EGFR-mt subgrp analysis of PACIFIC in which we see no diffs in PFS/OS with durva v PBO, &no concerning safety signals You know you’ve made it when ⁦@dhjutsw1⁩ comes to your poster ⭐️ ⁦⁦@CancerCentreIre⁩ ⁦@HopkinsThoracic⁩

NRG1 fusions are part of the NSCLC drivers family!! Zenocutuzumab, a HER2-HER3 bispecific antibody, has significant activity in a NRG1+ tumor agnostic population (n=83), ~50% being NSCLC. ORR=34% overall and 35% in NSCLC. Median DoR 9.1 mo and favorable safety profile. #ASCO22

#CedarsSinaiCancer at #ASCO22. Dr. Karen Reckamp @ReckampK is co-author on the poster “A phase 1/2 study of BLU-945 in patients with common activating EGFR-mutant non–small cell lung cancer: SYMPHONY trial in progress.”@ASCO @CedarsSinaiMed @CSCancerCare #NSCLC

Looking for a great Metworking opportunity? Come to our posters on METex14 w excellent lead authors @jennifermarksmd and #ASCO22 Merit awardee @Sokim_33 ! (Crediting @StephenVLiu for his great leadership on our Caris POA + coining the new and now licensed term: #Metwork)

#CedarsSinaiCancer at #ASCO22. Dr. Karen Reckamp @ReckampK is co-author on “Characterization of MET exon 14 skipping alterations in non–small cell lung cancer using whole transcriptome sequencing.”@ASCO @CedarsSinaiMed @CSCancerCare #NSCLC

https://t.co/aRdnnbBhs1

📣 #ASCO22 simultaneous pub: Lung-MAP study finds ramucirumab ➕ pembro improved OS in pts w #NSCLC previously treated w/ immune ✔️point inhibitors & chemo. https://t.co/M0zL95ddxD @ReckampK @DrRoyHerbstYale #lcsm

Congrats ⁦@DrRoyHerbstYale⁩ on being a Giant in Cancer Care! Live from Chicago ⁦@OncLive⁩

Ready to present. Excited about the data in the oral metastatic lung cancer session.